AOD-9604
A modified fragment of human growth hormone studied in earlier clinical trials; not FDA-approved.
What it is
AOD-9604 is a modified fragment of human growth hormone designed to isolate lipolytic (fat-related) activity without GH's growth effects. It went through real human trials for obesity in the 2000s — and failed to show meaningful weight loss, after which development stopped.
That failed-trial history matters: this is one of the few internet-famous peptides whose weight-loss question was actually tested in controlled human studies, with a negative answer. It later resurfaced through compounding and gray-market channels, marketed as if the trials had gone the other way.
What researchers have actually studied it for
Obesity, in completed human trials that did not demonstrate meaningful weight loss; development was discontinued.
How it works
The hGH 177-191 tail region with a stabilizing tyrosine — designed to trigger fat-cell lipolysis via beta-3-adrenergic-linked pathways without touching the GH receptor's growth signaling or IGF-1. The design goal succeeded; the clinical effect didn't follow.
Where it came from
Developed by Australian company Metabolic Pharmaceuticals from Monash University fragment research, AOD-9604 ran a full obesity program in the early 2000s. Phase 2b showed no meaningful weight-loss separation from placebo, development ended around 2007, and the molecule reappeared later in anti-obesity marketing that skips that chapter.
What the research record actually contains
- Multiple human trials, including a 300-patient phase 2b in obesity: no significant weight loss versus placebo.
- Good tolerability and no IGF-1 elevation across the program — the genuinely positive findings.
- Assorted animal work on cartilage and metabolism since; no human revival of efficacy.
What's known about risks
Unusually for this library, real trial safety data exists: well tolerated, no growth-axis activation. Its clinical history makes it more safety-characterized and less efficacious than almost anything else sold beside it.
Where it stands legally
Never approved; appears in compounding and gray-market channels, with eligibility the usual moving-target question. It has held US GRAS status as a food ingredient — a regulatory oddity that says nothing about efficacy.
Worth asking a licensed provider
- 1.Are you aware its human obesity trials failed — and what would justify using it anyway?
- 2.If fat loss is the goal, why not the GLP-1 class, where the evidence actually exists?
- 3.What would we measure to know it was doing anything at all?